Download presentation
Presentation is loading. Please wait.
Published byRudolf Pierce Cain Modified over 5 years ago
1
Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Chiara Lazzari, MD, Anna Spreafico, MD, Angela Bachi, PhD, Heinrich Roder, PhD, Irene Floriani, PhD, Daniela Garavaglia, PhD, Angela Cattaneo, PhD, Julia Grigorieva, PhD, Maria Grazia Viganò, MD, Cristina Sorlini, MD, Domenico Ghio, MD, Maxim Tsypin, PhD, Alessandra Bulotta, MD, Luca Bergamaschi, MD, Vanesa Gregorc, MD Journal of Thoracic Oncology Volume 7, Issue 1, Pages (January 2012) DOI: /JTO.0b013e f17 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1 Progression-free survival (PFS) according to baseline VeriStrat classification (HR, 0.54; 95% CI, 0.35–0.83; p = 0.005). Journal of Thoracic Oncology 2012 7, 40-48DOI: ( /JTO.0b013e f17) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2 Overall survival (OS) according to baseline VeriStrat classification (HR, 0.40; 95% CI, 0.26–0.61; p < ). Journal of Thoracic Oncology 2012 7, 40-48DOI: ( /JTO.0b013e f17) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
4
FIGURE 3 VeriStrat classification of individual patients in course of gefitinib therapy along with progression and death. Journal of Thoracic Oncology 2012 7, 40-48DOI: ( /JTO.0b013e f17) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.